NovoCure
NVCR
104 hedge funds and large institutions have $746M invested in NovoCure in 2017 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 37 increasing their positions, 24 reducing their positions, and 9 closing their positions.
414% more call options, than puts
Call options by funds: $24.4M | Put options by funds: $4.75M
222% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 9
54% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 24
31% more capital invested
Capital invested by funds: $567M → $746M (+$178M)
22% more funds holding
Funds holding: 85 → 104 (+19)
5% more ownership
Funds ownership: 37.2% → 42.2% (+5%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$17.9M |
| 2 |
AC
Ascend Capital
Orinda,
California
|
+$12.9M |
| 3 |
LCM
Laurion Capital Management
New York
|
+$10.9M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$8.83M |
| 5 |
CM
Castleark Management
Chicago,
Illinois
|
+$8.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$10.8M |
| 2 |
HCM
Highline Capital Management
New York
|
-$4.36M |
| 3 |
PCM
Peregrine Capital Management
Minneapolis,
Minnesota
|
-$4.3M |
| 4 |
SG
StepStone Group
La Jolla,
California
|
-$3.93M |
| 5 |
TA
Tamarack Advisers
Carlsbad,
California
|
-$3.17M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIM
101
Advantage Investment Management
Cedar Rapids,
Iowa
| $10K | +$9.83K | +500 | New |
|
|
AG
102
Advisor Group
Phoenix,
Arizona
| $8K | -$46.7K | -2,375 | -86% |
|
103
Federated Hermes
Pittsburgh,
Pennsylvania
| $2K | -$157 | -8 | -7% |
|
|
RBC
104
Roble Belko & Company
Sewickley,
Pennsylvania
| $2K | +$1.97K | +100 | New |
|
|
DCM
105
Driehaus Capital Management
Chicago,
Illinois
| – | -$748K | -43,211 | Closed |
|
|
WS
106
Wedbush Securities
Los Angeles,
California
| – | -$542K | -31,340 | Closed |
|
107
D.E. Shaw & Co
New York
| – | -$529K | -30,589 | Closed |
|
|
EMG
108
Ellington Management Group
Old Greenwich,
Connecticut
| – | -$358K | -20,700 | Closed |
|
|
QT
109
Quantbot Technologies
New York
| – | -$86K | -4,980 | Closed |
|
|
PAM
110
Panagora Asset Management
Boston,
Massachusetts
| – | -$32K | -1,830 | Closed |
|
111
Creative Planning
Overland Park,
Kansas
| – | -$17K | -1,000 | Closed |
|
|
NIT
112
NumerixS Investment Technologies
Vancouver,
British Columbia, Canada
| – | -$10K | -600 | Closed |
|
|
TDC
113
Thompson Davis & Co
Richmond,
Virginia
| – | -$4.91K | -250 | Closed |
|
NVCR Hedge Fund Activity: Q3 2017 in Review
104 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q3 2017, worth a combined $746M — up 31% from $567M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new NVCR positions and 9 closed out — a net gain of 20 holders — while 37 added to existing stakes and 24 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $17.9M. The largest seller was Rhenman & Partners Asset Management, cutting an estimated $10.8M.
- 104 institutional investors held NovoCure (NVCR) as of Q3 2017, up from 85 in Q2 2017.
- Funds reported $746M of NovoCure stock for Q3 2017, up 31% quarter-over-quarter.
- 29 funds opened new NovoCure positions in Q3 2017 and 9 closed out, a net change of +20 holders.
- The largest NovoCure buyer in Q3 2017 was Fidelity Investments, an estimated $17.9M added.
- The largest NovoCure seller in Q3 2017 was Rhenman & Partners Asset Management, an estimated $10.8M sold.
Based on aggregated 13F filings for Q3 2017.